SEC FORM 3/A SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Arix Bioscience plc

(Last) (First) (Middle)
20 BERKELEY SQUARE

(Street)
MAYFAIR, LONDON X0 W1J 6EQ

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/18/2018
3. Issuer Name and Ticker or Trading Symbol
LogicBio Therapeutics, Inc. [ LOGC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
10/19/2018
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock (1) (1) Common stock 2,279,023(1) (1) I See footnote(2)
1. Name and Address of Reporting Person*
Arix Bioscience plc

(Last) (First) (Middle)
20 BERKELEY SQUARE

(Street)
MAYFAIR, LONDON X0 W1J 6EQ

(City) (State) (Zip)
1. Name and Address of Reporting Person*
Arix Bioscience Holdings Ltd

(Last) (First) (Middle)
20 BERKLEY SQUARE

(Street)
MAYFAIR, LONDON X0 W1J6EQ

(City) (State) (Zip)
Explanation of Responses:
1. The Series B Convertible Preferred Stock is convertible into shares of common stock of LogicBio Therapeutics, Inc. (the "Issuer") at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock.
2. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
Remarks:
This filing amends the Form 3 filed on October 19, 2018 to reflect the addition of Arix Bioscience Holdings Limited as a Reporting Owner and signatory hereto. Arix Bioscience Holdings Limited had not yet obtained EDGAR access codes at the time of the prior Form 3 filing and has since obtained such codes.
Arix Bioscience Plc, by: /s/ James Rawlingson, Chief Financial Officer 10/25/2018
Arix Bioscience Holdings Limited, by: /s/ James Rawlingson, Authorized Officer 10/25/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.